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Abstract
ZD9331 is an antifolate drug that potently and specifically inhibits thymidylate synthase (TS). In contrast with TS inhibitors such as
raltitrexed, it cannot be polyglutamated, leading to antitumour activity independent of folylpolyglutamyl synthetase (FPGS) activity. The
growth inhibition IC50 values for ZD9331 and raltitrexed were determined for a panel of 18 human tumour cell lines, that included six colon
and six ovarian. The colon lines largely displayed overlapping sensitivities to both drugs with only one of the six lines being drug resistant. In
contrast, the ovarian cell lines displayed non-overlapping sensitivities with four being highly resistant to raltitrexed and only one was cross-
resistant to ZD9331. Studies were undertaken to explain these results. The colon and ovarian cell lines were characterised for TS activity, and
TS and FPGS mRNA expression. TS activity correlated with sensitivity to ZD9331 (r = 0.50; p = 0.097) and raltitrexed (r = 0.74; p = 0.0063).
Provided the data from the highly drug-resistant cell lines (BE and 41 M) were omitted, TS mRNA expression levels also correlated with
ZD9331 (r = 0.77; p = 0.013) and raltitrexed IC50 (r = 0.84; p = 0.0031). FPGS mRNA expression correlated with higher sensitivity to
raltitrexed relative to ZD9331 (higher ZD9331/raltitrexed IC50 ratios) (r = 0.62; p = 0.048). Similarly, cell lines with IC50 ratios >median
expressed a 1.8-fold higher median level of FPGS mRNA ( p = 0.0087) compared with those with ratiosVmedian. The four ovarian and one
colon cell line that were relatively more sensitive to ZD9331 expressed FPGS mRNAVmedian ( p = 0.061). Thus, ZD9331 overcomes
resistance to raltitrexed in ovarian tumour cell lines expressing low levels of FPGS. These data, and others demonstrating a lack of cross-
resistance between cisplatin and ZD9331, support the clinical evaluation of ZD9331 in platinum-refractory ovarian cancer. D 2002 Published
by Elsevier Science B.V.
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1. Introduction
Thymidylate synthase (TS) is the rate-limiting enzyme in
a key pathway leading to the synthesis of thymidine
nucleotides and consequently is one of several enzymes
expressed early in S-phase that regulate DNA synthesis, cell
cycle progression and proliferation. Recent evidence sug-
gests that TS is an RNA binding protein, putatively binding
and regulating the translation of itself, p53, c-myc and other
mRNAs of growth regulatory proteins [1]. The emerging
importance of TS as part of a coordinated S-phase driving
machinery may explain why drugs that have direct or
indirect inhibition of this enzyme, as at least part of their
mechanism of action, remain widely used in cancer medi-
cine. These include the antifolate, methotrexate and the
fluoropyrimidines (5-fluorouracil and its prodrugs). More
recently, the highly specific antifolate inhibitor of TS,
raltitrexed, a polyglutamatable drug has become clinically
available for the treatment of advanced colorectal cancer
[2,3]. Predictably, the differences in metabolism, target
specificity and TS binding site interactions of these drugs
leads to them possessing incompletely overlapping spectra
of antitumour activity and toxic side effects. An under-
standing of these differences led to the design and discovery
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of the folate-based TS inhibitor, ZD9331 (TS Ki = 0.4 nM)
[4,5]. In many respects, it shares properties with raltitrexed
in that it is transported into cells via the reduced-folate
carrier (RFC), binds to the folate-binding site of TS and
does not inhibit other metabolic pathways. However,
ZD9331 is not metabolised by folylpolyglutamyl synthetase
(FPGS) and in contrast with raltitrexed (polyglutamates),
ZD9331 freely effluxes across the plasma membrane. Thus,
it was predicted that ZD9331 would need to be administered
in a more frequent dosing schedule than the 3-weekly short
infusion used for raltitrexed. However, clinical studies
showed that TS inhibition recovered slowly after adminis-
tration of ZD9331 and was attributed to a slow terminal
phase of plasma clearance in humans. The schedule primar-
ily being used for phase II evaluation is a short infusion on
days 1 and 8 in a 3-weekly schedule [6].
Cell lines with increased TS expression through acquired
resistance to TS inhibitors display cross-resistance to ralti-
trexed and ZD9331 [7]. However, those expressing low
levels of FPGS are resistant to raltitrexed but not to
ZD9331. This implies that TS and FPGS gene expressions
will determine intrinsic sensitivity to these drugs in exper-
imental and clinical settings. Indeed, in a small advanced
colorectal cancer study, it was shown that low TS mRNA
levels in metastatic tumour biopsies significantly predicts
for increased response and survival to raltitrexed [8].
In this present study, we have used a panel of 18 human
tumour cell lines (not previously exposed to antifolates) to
evaluate the relative activity of ZD9331 and raltitrexed.
Tumour types represented are ovarian, colon, lung, meso-
thelioma and vulvular. The study focuses on some molec-
ular determinants of response to raltitrexed and ZD9331 in
the six ovarian and six colon cell lines because they
represent tumour types relatively clinically resistant and
sensitive to raltitrexed, respectively. The response rate in
platinum-refractory ovarian cancer was f 7% while first-
line treatment in colorectal cancer patients was f 20% [9].
Across the whole cell line panel, these drugs displayed
incompletely overlapping spectra of antitumour activity.
Interestingly, ZD9331 overcame resistance to raltitrexed in
ovarian cell lines expressing low FPGS mRNA. Taken
together, these data predict that ZD9331 may have greater
clinical activity than raltitrexed in this tumour type. Fur-
thermore, we have demonstrated that ZD9331 and cisplatin,
the commonly used first-line of treatment for ovarian
cancer, are non-cross-resistant in the ovarian tumour cell
lines.
2. Experimental procedures
2.1. Cell lines, media and drugs
Colon tumour cell lines HT29, SW620, SW480, Mawi,
BE and LoVo were obtained from stocks held at the Institute
of Cancer Research, UK. The biological details of the
ovarian cell lines have been described previously [10,11].
Two of the ovarian cell lines had been obtained from
patients previously treated with cytotoxic drugs: platinum-
based drugs (CH1 and PXN94), thiotepa (SKOV-3). All cell
lines were grown as adherent monolayers in DMEM
medium (Gibco, Paisley, Scotland) plus 10% (v/v) dialysed
foetal calf serum (ICN Flow, Thames, Oxfordshire, UK), 50
Ag/ml gentamicin, 2.5 Ag/ml amphotericin B, 2 mM gluta-
mine (all from Gibco), 5.5 Ag/ml insulin and 0.44 Ag/ml
hydrocortisone in a 10% CO2, 90% air atmosphere. All cell
lines were negative for mycoplasma as measured by the
Strategen PCR kit (Cambridge, UK).
RTX and VDX were obtained from AstraZeneca, PLC
and cisplatin (CDDP) was obtained from Sigma-Aldrich
(Poole, Dorset, UK). The antifolates were dissolved in 0.15
M NaHCO3 (stored at  20 jC for up to 3 months) at 10
mM and CDDP in saline at 2 mM. Dilutions were in
unsupplemented medium.
2.2. Growth inhibition assays
Single cells (harvested after trypsinisation of a f 70%
confluent flask) were seeded at 1 to 3 103 cells/well (in
160 Al) into 96-well plates. After overnight incubation to
allow attachment, drug dilutions (40 Al) were added at
various concentrations in quadruplicate wells. After incuba-
tion for 96–120 h (three to four population doublings)
growth inhibition was then assessed using an MTT assay
as a surrogate end-point of viability as described previously
[12,13]. The IC50 was defined as the concentration of
compound required to inhibit cell growth/reduce absorbance
at 540 nm by 50%.
2.3. TS activity measurements
The rate of [3H]20 release from 5-[
3H]dUMP was meas-
ured in freshly prepared supernatants from each cell line as
described previously [7,14]. The results are expressed as
nmol product formed/h/mg protein.
2.4. TS and FPGS mRNA expression by Northern blotting
RNA was extracted from exponentially growing cells
using guinidinium isothiocyanate and separated through a
cesium chloride gradient [15]. RNA concentrations were
determined spectrophotometrically. RNA samples were sep-
arated on 1.2% formaldehyde gels and transferred to
Hybond N nylon membranes by capillary transfer. The
human FPGS probe was a full-length cDNA EcoR1 restric-
tion of pTZ18U-hFPGS plasmid [16]. The TS probe was a
750-bp Pst1 fragment of the mouse TS cDNA from pMTS-3
plasmid [17]. The GAPDH probe was a 1.3-kb Pst1 restric-
tion fragment of a rat cDNA. Probes were random prime
labelled using a commercial kit (Amersham Pharmacia,
UK). Hybridization, washing, visualisation and quantifica-
tion were as previously described [18].
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Two sets of RNA were prepared from each of the six
ovarian cell line and each set subjected to Northern blotting
four times. Each blot included all six ovarian cell lines and
also a lane loaded with RNA from the HT29 colon cell line
as a reference. Following phosphoimaging, the bands for
TS, FPGS and GAPDH for each cell line were expressed as
the percentage of the total sum above background (this
allows for any differences in exposure times for one or more
of the RNA species of interest between experiments). TS
and FPGS for each cell line in each blot were then expressed
relative to GAPDH (to accommodate any differences in
loading). The results are expressed as the mean of each set
of RNA which in turn is expressed relative to the mean
value for HT29. This allowed the results to be compared
with those for the colon tumour cell lines that were
determined separately from the ovarian tumour cell lines.
For the colon lines, each blot included RNA from all six cell
lines. One set of RNA was subjected to Northern blotting
four times and the second set three times. The mean of
results of each set was expressed relative to HT29 as
described above.
2.5. Statistical analyses
The non-parametric Spearman correlation was used to
quantitate the degree of linear association between two
variables (GraphPad Instat). Linear regression was used to
fit a line to data not containing significant outliers (Graph-
Pad Prism). The non-parametric Mann–Witney test was
used to test whether variables differed between two subsets
of a group.
In some cases the subsets were separated with respect to
their position above or below the median for the group.
Some data were anlysed by a 2 2 contingency table
(Fischers exact test; GraphPad Prism).
3. Results
3.1. Sensitivity of 18 human tumour cell lines to ZD9331
and raltitrexed
The 18 human tumour cell lines displayed a wide range
of sensitivities to raltitrexed and ZD9331. A correlation was
observed between the IC50 for the two drugs (r = 0.72;
p = 0.0007) although there were a significant number of
outliers illustrated by a weak linear correlation (r2 = 0.27;
p = 0.026; data not shown). The log IC50s for raltitrexed and
ZD9331 were calculated for all cell lines and the medians
generated for each drug. These medians were subtracted
from the individual log IC50s and presented as difference
median plots for each drug in Fig. 1. This gives broad
Fig. 1. Difference median plots for ZD9331 and raltitrexed in 18 human tumour cell lines. The IC50 data for ZD9331 and raltitrexed were log-transformed and
medians derived for each drug. The plot was generated by subtracting the medians from the individual IC50s.
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patterns of activity of the two drugs with positive values
representing relative resistance and negative values repre-
senting relative sensitivity. The median is generated from a
relatively low number of cell lines compared with the 60
lines in the National Cancer Institute (NCI) panel and
therefore values falling slightly on either side of the median
should not be over-interpreted in terms of relative sensitiv-
ities. The BE colon cell line was highly resistant to both
Fig. 2. Difference median plots for relative sensitivity to ZD9331 and raltitrexed in 18 human tumour cell lines. The ratios of the IC50 ZD9331/IC50 raltitrexed
were log-transformed and the median subtracted.
Table 1
Growth inhibition and target expression in human ovarian and colon tumour cell lines
Histological Growth inhibition IC50 (AM)a ZD9331 IC50/ TS activity mRNA relative to GAPDH
tumour type
ZD9331 Raltitrexed
raltitrexed IC50 (nmol/h/mg protein)
b (normalised to HT29)c
TS FPGS
SKOV3 ovarian 0.098 0.0023 43 2.6 2.5 1.2
HX62 ovarian 0.024 0.0049 4.9 8 1.5 0.49
PXN94 ovarian 0.081 0.032 2.5 13 2.6 0.57
CH1 ovarian 0.068 0.017 4.0 19 2.6 0.71
A2780 ovarian 0.068 0.022 3.1 16 2.6 0.44
41M ovarian 15 0.039 385 8 0.88 0.71
Median ovarian 0.075 0.020 4.5 11 2.6 0.64
HT29 colon 0.036 0.0019 19 2.5 1.0 1.0
SW620 colon 0.031 0.0020 16 6.6 1.1 0.80
LoVo colon 0.023 0.0023 10 2.3 0.8 0.44
SW480 colon 0.051 0.0021 24 7.1 1.2 0.64
MaWi colon 0.042 0.0025 17 2.9 1.3 0.91
BE colon f 10 f 10 – 14 0.85 0.53
Median colon 0.039 0.0022 17 4.8 1.1d 0.72
Median colon + ovarian 0.06 0.0037 – 7.6 1.2 0.68
Median BE 0.051 0.0025 15 7.1 1.3 0.71
a Mean of 3 to 6 separate experiments.
b Mean of 5 to 10 separate experiments.
c TS/GAPDH or FPGS/GAPDH ratios for each cell line are expressed relative to the HT29/GAPDH ratio.
d Significantly different from ovarian ( p< 0.05).
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drugs while data for the other five colon lines clustered
close to the median (Fig. 1). In contrast, four of the six
ovarian lines (PXN94, CH1, A2780 and 41 M) were
resistant to raltitrexed while only one (41 M) was resistant
to ZD9331. The four lung cell lines in the panel generally
displayed high sensitivity to raltitrexed and particularly to
ZD9331.
More information regarding the mechanisms underlying
the different patterns of drug activity is gained by presenting
the data as the ratio of the IC50 of ZD9331 to the IC50 of
raltitrexed for each cell line. These ratios were log-trans-
formed and the median subtracted and are presented in Fig.
2. Four of the five colon cell lines were relatively more
sensitive to raltitrexed, while two of the four lung and four
of the six ovarian cell lines were relatively more sensitive to
ZD9331. The ovarian panel displayed the largest range of
relative sensitivities, with PXN94, A2780, CH1 and HX62
being markedly more sensitive to ZD9331 than raltitrexed.
In contrast, the SKOV3 and 41 M cell lines were relatively
more sensitive to raltitrexed than ZD9331.
3.2. TS activity, TS mRNA and FPGS mRNA in 12 human
ovarian and colon tumour cell lines
The 12 colon and ovarian cell lines displayed a 3.3-fold
variation in TS mRNA levels and an 8-fold variation in TS
activity (Table 1). A relationship was found between TS
mRNA and TS activity that was not quite statistically
significant (r= 0.45, p = 0.072; data not shown). This was
largely because two cell lines, SKOV3 and BE had dis-
cordant values, with TS activity low relative to the mRNA
level for SKOV3 and vice versa for BE. If these cell lines
were excluded from the dataset, the correlation became
significant (r= 0.80; p = 0.0072) (data not shown). FPGS
mRNA expression varied 2.7-fold among the 12 colon and
ovarian cell lines. There was no relationship between FPGS
and TS mRNA expression.
The median TS activity level was 2.3-fold higher in the
ovarian cell line panel compared with the colon cell line
panel that was not quite statistically significant (11 and 4.8
pmol/h/mg protein, respectively; p = 0.093). However, there
was 2.4-fold higher median TS mRNA expression in the
ovarian compared with the colon panel (median = 2.6 and
1.1, respectively; p = 0.026) (Table 1). Median FPGS
mRNA levels were lower in the ovarian panel than the
colon panel (0.64 and 0.72, respectively) but this difference
was not statistically different.
Table 2
Relationship between growth inhibition and target expression in colon and
ovarian human tumour cell lines
TS activity mRNA
TS FPGS
ZD9331 IC50 all cell lines r = 0.50 r = 0.17 r = 0.17
p= 0.097 p= 0.60 p= 0.60
BE r = 0.46 r = 0.41a r = 0.26
p= 0.16 p= 0.20 p= 0.45
Raltitrexed IC50 all cell lines r= 0.74 r = 0.1 r = 0.45
p= 0.0063 p= 0.63 p= 0.14
BE r= 0.72 r = 0.44b r = 0.43
p= 0.014 p= 0.18 p= 0.19
ZD9331/ BE r = 0.53 r = 0.61 r= 0.62
raltitrexed IC50
c p= 0.094 p= 0.052 p= 0.048
The non-parametric Spearman correlation was used to quantitate the degree
of linear association between two variables. TS mRNA vs. FPGS mRNA:
r = 0.042; p= 0.90.
a Removal of 41 M gives r = 0.77; p= 0.013.
b Removal of 41 M gives r= 0.84; p= 0.0031.
c No ratio can be generated for the BE cell line.
Fig. 3. Relationship between FPGS mRNA expression and relative
sensitivity to raltitrexed compared with ZD9331. FPGS/GAPDH mRNA
(relative to HT29) is plotted against the ratio of the ZD9331 IC50/raltitrexed
IC50 for each cell line. A ratio could not be generated for BE (IC50 for both
cell lines >10 AM).
Table 3
Target expressions stratified for growth inhibition in colon and ovarian
tumour cell lines
Inhibition of TS mRNA
cell growth
(IC50)
activity
TS FPGS
ZD9331 all cell Vmedian 4.8 1.2 0.72
IC50IC50 lines > median 14 2.6 0.64
p= 0.026 p= 0.24 p= 0.82
BE Vmedian 4.8 1.2 0.72
> median 13 2.6 0.71
p= 0.052 p= 0.082a p = 0.93
Raltitrexed all cell Vmedian 2.8 1.2 0.86
IC50 lines > median 14 2.1 0.55
p= 0.0022 p= 0.31 p= 0.093
BE Vmedian 2.8 1.2 0.86
> median 13 2.6 0.57
p= 0.0043 p= 0.13a p = 0.13
ZD9331/ BE Vmedian 13 2.6 0.49
RTX IC50
b > median 4.8 1.2 0.86
p= 0.13 p= 0.18 p = 0.0087
The non-parametric Mann–Whitney test was used to test whether the
variables differed between IC50 values above or below the median.
a p= 0.032 if 41 M cell line data omitted.
b Cannot be generated for the BE cell line.
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3.3. Determinants of sensitivity—statistical analyses
The relationships between cell line sensitivity to the
drugs and target expression profiles are given in Table 2.
TS activity for all cell lines correlated with raltitrexed IC50s
(r = 0.74; p = 0.0063) but not quite significantly with
ZD9331 IC50s (r = 0.50; p = 0.097). TS mRNA expression
did not correlate with sensitivity to either drug unless the
data for the two highly drug resistant BE and 41 M cell lines
were omitted (raltitrexed, r = 0.84, p = 0.0031; ZD9331,
r = 0.77, p = 0.013).
There was an inverse relationship between FPGS mRNA
expression and raltitrexed IC50s but this was not statistically
significant (r = 0.45; p = 0.14). However, a significant
correlation (r= 0.62; p= 0.048) was found between FPGS
mRNA expression and the relative ZD9331/raltitrexed IC50
ratios, i.e. increasingly high levels of FPGS expression are
associated with increasing sensitivity to raltitrexed relative
to ZD9331 (Fig. 3).
Table 3 stratifies drug sensitivities (IC50s) above and
below their respective medians and then compares the gene
expressions/activity for each group. Cell lines with higher
sensitivity to ZD9331 or raltitrexed (IC50Vmedian) dis-
played a significantly lower ( p < 0.05) median TS activity
level (3- and 5-fold, respectively). Those with raltitrexed
IC50Vmedian expressed a 1.6-fold higher median FPGS
mRNA level ( p = 0.093). However, those with ZD9331/
raltitrexed IC50 ratiosVmedian expressed a 1.8-fold lower
median level of FPGS ( p = 0.0087) compared with those
with ratios>median. These data, which is shown graphically
in Fig. 4, are consistent with FPGS mRNA expression being
a determinant of cell line sensitivity to raltitrexed relative to
ZD9331. The five cell lines relatively more sensitive to
ZD9331, which included four ovarian, had FPGS mRNA
levelsV to the median. Only two of the six cell lines
relatively more sensitive to raltitrexed (one ovarian and
one colon) had FPGS mRNA levelsVmedian ( p = 0.061;
Fischers exact test).
Fig. 4. FPGS mRNA expression stratified for cell line relative drug
sensitivity. FPGS/GAPDH mRNA (relative to HT29) is stratified for cell
lines with ZD9331 IC50/raltitrexed IC50 ratios above and below the median.
O = ovarian; C = colon. No ratio could be generated for BE.
Fig. 5. Difference median plots for ZD9331 and cisplatin in six human ovarian tumour cell lines. The IC50 data for ZD9331 and cisplatin were log-transformed
and medians derived for each drug. The plot was generated by subtracting the medians from the individual IC50s.
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3.4. Relative sensitivity of the ovarian cell line panel to
ZD9331 and cis-platinum
The relative sensitivity of ZD9331 was compared with
that of published data for cisplatin from these laboratories.
Three cell lines (CH1, A2780 and 41 M) are platinum-
sensitive (IC50s 0.1–0.3 AM), and three (SKOV3, HX62
and PXN94) are relatively platinum-resistant (IC50s 3–13
AM). In contrast, the 41 M cell line is highly resistant to
ZD9331 and the others, particularly the HX62, are highly
sensitive to ZD9331. Thus, no cross-resistance is observed
between these two drugs (Fig. 5).
4. Conclusions and perspectives
4.1. Cell line sensitivity to raltitrexed and ZD9331
Different classes of TS inhibitors have been developed
in recent years, each with different cellular pharmacology
and specificity for the enzyme. Although drug-resistant cell
lines (usually with high levels of in vitro acquired resist-
ance) have been useful in describing the different patterns
of activity of these drugs, they do not necessarily reflect
patterns of resistance in vivo. Thus, it can be more relevant
to use intrinsically resistant lines, or lines developed from
patients resistant to chemotherapy, to evaluate tumour
sensitivity. However, predicting clinical sensitivity to new
agents by extrapolation from in vitro cell lines is difficult.
The problem has been addressed, in part, by the use of
panels of human tumour cell lines (such as the NCI in vitro
cell line panel), with several representatives from each of a
number of tumour types [19]. This allows the assessment
of the relative sensitivity of tumour types to given agents,
by expressing activity relative to a mean or median for all
the cell lines, and the sensitivity of individual cell lines
within that panel. This information can also be used in the
context of gene expression patterns to tease out potential
determinants of sensitivity and resistance to anticancer
agents. This type of approach has been applied in this
present study and has provided a rationale for the clinical
development of ZD9331 in solid tumours such as ovarian
cancer.
This study has focused primarily on colon and ovarian
tumours although other cell lines have been included in
order to derive a more representative median growth
inhibition IC50 value. Five of the six colon tumour cell
lines were uniformly sensitive to raltitrexed while only two
of the six ovarian tumour cell lines displayed a similar level
of sensitivity. Thus, the cell line panel broadly reflects the
clinical sensitivity and resistance to raltitrexed in clinical
colon and ovarian cancer [9]. Interestingly, ZD9331 was
more broadly active than raltitrexed and overcame resist-
ance to raltitrexed in three of four highly raltitrexed-
resistant ovarian cell lines (PXN94, CH1 and A2780). A
further cell line, HX62, was also relatively more sensitive
to ZD9331 than raltitrexed. Although the number of cell
lines evaluated was small, the data suggests that ZD9331
may have greater clinical activity than raltitrexed in ovarian
cancer.
4.2. Molecular determinants of sensitivity to TS inhibitors
In order to explore the molecular basis for the differences
observed in sensitivity to the raltitrexed and ZD9331, TS
and FPGS gene expressions were measured in the colon and
ovarian cell lines. Despite the small number of cell lines
examined, a number of correlations were observed, some of
which attained significance at the 95% confidence level.
The activity of the target, TS, significantly correlated with
sensitivity to raltitrexed in all of the 12 colon and ovarian
cell lines ( p = 0.0063), which is in contrast with reported
data for 13 colon tumour cell lines [20]. TS activity
correlated with ZD9331 sensitivity ( p = 0.097). Our data
are broadly consistent with a report that TS activity is
related to Nolatrexed sensitivity in colon and leukaemia
cell provided that the data for three cell lines were omitted
[21]. A difference between these reports and our data may
relate to the method of calculation of the activity measure-
ments. We have normalised data to protein concentration
rather than cell number. This may account for the very
different ranking of cell lines common to this report and that
of Estlin et al. [21]. Normalising to protein content may also
explain our better relationship between TS activity and
mRNA expression. However, the number of cell lines
included in both of these studies is small, and consequently,
outliers often markedly reduced the significance of the
correlations. Recently, Grem et al. [19] performed a similar
correlation across most of the NCI 60 human tumour cell
line panel. They reported only a weak to moderate correla-
tion between TS protein and TS mRNA (r= 0.45).
TS mRNA did not correlate with sensitivity to ZD9331
and raltitrexed. However, if the data for the highly resistant
41 M and BE cell lines were omitted, significance was
attained. Those cell lines that displayed ZD9331 or ralti-
trexed IC50s higher than the median had a 2-fold higher
median TS mRNA level that was statistically significant if
the data for the highly drug resistant 41 M and BE cell lines
were omitted. These data are consistent with clinical reports
that TSmRNA expression predicts for response and survival
to 5-FU or raltitrexed [8,22].
Possible explanations for the failure of TS expression to
correlate with sensitivity to 5-FU or 5-fluorodeoxyuridine
(5-FdUrd) in the NCI human tumour panel are given by
Grem et al. [19]. They include the short duration of the
assay (48 h) relative to the median cell doubling time of 34
h (18–38 h) with the general failure to induce cytotoxicity.
This may explain why the median 96 h IC50s of 5-FdUrd in
our panel of six colon tumour cell lines was 0.008 AM
compared with a GI50 of 1.2 AM for the six colon cell lines
in the NCI panel. Two cell line examples common to both
panels are the SW620 and HT29 in which we reported IC50
A.L. Jackman et al. / Biochimica et Biophysica Acta 1587 (2002) 215–223 221
values of 0.007 and 0.0067 AM for 5-FdUrd [2], whereas the
NCI reported GI50s of 23 and 0.75 AM, respectively.
Furthermore, we use MTT as a surrogate end-point of
growth inhibition as we have found this a more reliable
end-point for TS inhibitors than SRB (used by the NCI and
others). TS inhibition induces megaloblastosis and leads to
an increase in total protein content, that is detectable until
lethality and cell loss has occurred. A consequence can be
shallow dose–response curves and high IC50s. Grem et al.
[19] argued that the high dThd concentration in the medium
did not contribute to the lack of correlation between
fluoropyrimidine sensitivity and TS expression because
the concentration is lower than that often reported to reverse
TS inhibition. However, it is important to note that in vitro,
dThd is high at the time of drug addition and then decreases
largely as a function of proliferation rate as it becomes
depleted through its incorporation into DNA [23]. Thus,
plating density and the rate of DNA synthesis (related to cell
doubling times) determine how rapidly dThd falls to a
concentration that will not protect cells from TS inhibition.
This may explain why, in contrast with 5-FdUrd, the median
5-FU GI50 in the NCI colon panel (6.3 AM) is very similar to
our own IC50 value of 4.7 AM. The mechanism of action of
5-FU partly relates to its RNA-directed effects and would
therefore be less affected by the dThd in the medium.
FPGS is the enzyme responsible for catalysing the
formation of the active raltitrexed polyglutamates, and in
this study, FPGS mRNA levels did not correlate with
sensitivity to raltitrexed. This may be due, at least in part,
to post-translational regulation of this enzyme [24]. How-
ever, Van Triest et al. [20] measured FPGS activity in a
panel of 13 non-selected colon cell lines and did not find a
positive correlation with sensitivity to raltitrexed. Never-
theless, FPGS activity is itself a fairly crude assay in that it
only measures mono to diglutamate formation and does not
necessarily predict for the formation of the important long
chain-length polyglutamates of raltitrexed. Data not pre-
sented showed a significant correlation between FPGS
mRNA and raltitrexed (polyglutamate) accumulation in 11
of the 12 cell lines after 24 h exposure to 0.1 AM [3H]-
raltitrexed (r= 0.75; p = 0.0049). Data from the HX62 was
excluded from the analyses because of the discordantly high
raltitrexed uptake relative to its FPGS mRNA expression.
However, no correlation was seen between drug accumu-
lation and raltitrexed sensitivity.
These data are consistent with other reports that suggest
that the measurement of a single gene expression, activity or
drug concentration in small numbers of cell lines do not
provide highly significant statistical correlations with drug
sensitivity. Furthermore, the fact that correlations are gen-
erally weak reinforces the belief that drug sensitivity is
multifactorial and will rarely be attributable to expression of
a single gene. Hence, expression of components of down-
stream pathways including the uracil–DNA misincorpora-
tion pathway and those driving survival and apoptosis may
be significant. This is supported by data from experimental
cell lines, including those transfected with dUTPase or bcl-
2, that are less sensitive to raltitrexed and ZD9331 [25,26].
4.3. Rationale for the use of ZD9331 in ovarian cancer
The primary purpose of the gene expression measure-
ments was to explain the relative sensitivity of the ovarian
cell lines to ZD9331 compared with raltitrexed and therefore
to provide a rationale for the clinical evaluation in this
disease. We rationalised that downstream gene expressions
that may impact on sensitivity would commonly affect both
drugs, and therefore ZD9331/raltitrexed IC50 ratios may
correlate with FPGS expression or raltitrexed polyglutamate
formation. Indeed, a significant correlation with FPGS
mRNA expression was observed. However, there was also
a trend towards an inverse relationship between the IC50
ratio and TS activity or TS mRNA suggesting that cell lines
with high TS were relatively more sensitive to ZD9331 than
raltitrexed. Similar observations were made when relative
drug sensitivity was stratified above and below the median
and correlated with gene expressions. Furthermore, the four
ovarian cell lines (HX62, PXN94, CH1 and A2780) and the
one colon line (LoVo) that were relatively less sensitive to
raltitrexed than ZD9331, expressed FPGS mRNA lev-
elsVmedian ( p = 0.061; Fischers exact test).
An important conclusion from the study is that ZD9331
largely overcomes resistance to raltitrexed in ovarian tumour
cell lines expressing low FPGS mRNA, and may also
overcome resistance due to small elevations in TS expres-
sion. Recently, we reported higher TS mRNA and lower
FPGS mRNA (median = 9.4 and 6.2 103 relative to h-
actin, respectively) in 42 ovarian tumours compared with 20
metastatic colon tumours (median = 5.6 and 26 103 rela-
tive to h-actin, respectively, p < 0.05) [8,27]. Taken together,
these data may explain the low clinical response rate to
raltitrexed in ovarian cancer, and predict for increased
sensitivity to ZD9331. Furthermore, the lack of cross-
resistance between cisplatin and ZD9331 in the ovarian cell
line panel supports the further clinical evaluation of ZD9331
in platinum-refractory ovarian cancer. Finally, a relevant
observation reported elsewhere by ourselves, is that ZD9331
can be alternatively transported into tumours via the a-folate
receptor (a-FR) and has high activity in a-FR overexpress-
ing cell lines [28]. However, this activity is not observed in
cell lines grown in commercial media that contain supra-
physiological concentrations of folic acid. Thus, the
ZD9331 sensitivity described herein cannot be attributed
to a-FR mediated uptake. Approximately, 90% of ovarian
tumour specimens overexpress this receptor [29] and we
predict that this will contribute to ZD9331 clinical activity
in ovarian cancer.
In summary, experimental data supports the clinical
evaluation of ZD9331 in platinum-refractory ovarian cancer.
Potential molecular predictors of response are TS and a-FR
and we recommend incorporation of these markers into
further ovarian cancer clinical studies.
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